MDT

96.42

+0.17%↑

146.88

-0.15%↓

VEEV

230.71

-1.7%↓

HQY

83.52

-4.3%↓

PHR.US

16.41

-3.07%↓

MDT

96.42

+0.17%↑

146.88

-0.15%↓

VEEV

230.71

-1.7%↓

HQY

83.52

-4.3%↓

PHR.US

16.41

-3.07%↓

MDT

96.42

+0.17%↑

146.88

-0.15%↓

VEEV

230.71

-1.7%↓

HQY

83.52

-4.3%↓

PHR.US

16.41

-3.07%↓

MDT

96.42

+0.17%↑

146.88

-0.15%↓

VEEV

230.71

-1.7%↓

HQY

83.52

-4.3%↓

PHR.US

16.41

-3.07%↓

MDT

96.42

+0.17%↑

146.88

-0.15%↓

VEEV

230.71

-1.7%↓

HQY

83.52

-4.3%↓

PHR.US

16.41

-3.07%↓

Home・Aktien・Cogent Biosciences Inc

Cogent Biosciences Inc

Open

35.07 1.62

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

33.82

Max

35.06

Schlüsselkennzahlen
By Trading Economics
Einkommen	-7.4M -81M
EPS	-0.5
Angestellte	205
EBITDA	-6.8M -79M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+36.91% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	24. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	3.1B 5.3B
Vorheriger Eröffnungskurs	33.45
Vorheriger Schlusskurs	35.07

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

4.88 / 5.87 Unterstützung & Widerstand

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Jan. 2026, 23:54 UTC

Market Talk

CBA Could Underperform Again in 2026 -- Market Talk

12. Jan. 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. Jan. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

12. Jan. 2026, 23:43 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

12. Jan. 2026, 23:18 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12. Jan. 2026, 21:56 UTC

Market Talk

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Jan. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

12. Jan. 2026, 21:50 UTC

Market Talk

Ergebnisse

Auto & Transport Roundup: Market Talk

12. Jan. 2026, 21:18 UTC

Market Talk

Global Equities Roundup: Market Talk

12. Jan. 2026, 21:18 UTC

Market Talk

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12. Jan. 2026, 20:54 UTC

Ergebnisse

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12. Jan. 2026, 20:48 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12. Jan. 2026, 20:33 UTC

Market Talk

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12. Jan. 2026, 20:18 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12. Jan. 2026, 20:18 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12. Jan. 2026, 19:39 UTC

Market Talk

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12. Jan. 2026, 19:36 UTC

Market Talk

Gold and Silver Set New Records on Fed Probe -- Market Talk

12. Jan. 2026, 19:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. Jan. 2026, 19:33 UTC

Market Talk

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12. Jan. 2026, 19:24 UTC

Akquisitionen, Fusionen, Übernahmen

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12. Jan. 2026, 19:22 UTC

Akquisitionen, Fusionen, Übernahmen

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12. Jan. 2026, 18:21 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12. Jan. 2026, 18:20 UTC

Akquisitionen, Fusionen, Übernahmen

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12. Jan. 2026, 18:19 UTC

Market Talk

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12. Jan. 2026, 18:16 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12. Jan. 2026, 18:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12. Jan. 2026, 18:09 UTC

Market Talk

Baidu's Outlook Bodes Well For Shares -- Market Talk

12. Jan. 2026, 18:01 UTC

Akquisitionen, Fusionen, Übernahmen

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12. Jan. 2026, 18:00 UTC

Market Talk

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

36.91% Vorteil

12-Monats-Prognose

Durchschnitt 48.7 USD 36.91%

Hoch 67 USD

Tief 34 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

Buy

Halten

Sell

Basierend auf 11 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cogent Biosciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.